Fluvastatin Sodium 20 mg, 40 mg, 80 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets / Capsules

Available Strengths: 20 mg, 40 mg, 80 mg

Reference Brands: Lescol (USA), Canef (EU), Vastin (EU)

Category: Heart Disorder

Fluvastatin Sodium is a Heart Disorder product available as Tablets / Capsules in strengths 20 mg, 40 mg, 80 mg. It corresponds to the reference brands Lescol (USA), Canef (EU), Vastin (EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Fluvastatin sodium is the sodium salt of a synthetic lipid-lowering agent that also exhibits potential antineoplastic activity. As a selective HMG-CoA reductase inhibitor, it competitively inhibits the hepatic enzyme responsible for converting HMG-CoA to mevalonate, a key step in cholesterol biosynthesis. This action leads to reduced plasma cholesterol and lipoprotein levels, contributing to cardiovascular risk reduction in patients with hypercholesterolemia or mixed dyslipidemia.

Beyond its lipid-lowering effects, fluvastatin modulates immune responses by suppressing major histocompatibility complex II (MHC II) expression on interferon gamma-stimulated antigen-presenting cells, such as vascular endothelial cells. Additionally, by inhibiting mevalonate-derived intermediates like dolichol, geranylpyrophosphate (GPP), and farnesylpyrophosphate (FPP), fluvastatin interferes with the isoprenylation of intracellular G-proteins such as Ras and Rho. This mechanism can induce antiangiogenic, pro-apoptotic, and antimetastatic effects in susceptible tumor cells, highlighting its potential in adjunctive cancer therapy.

Fluvastatin is administered orally as immediate or extended-release tablets under medical supervision, providing dual benefits in cardiovascular protection and potential anticancer activity. Its well-established safety profile and pharmacological versatility make it a valuable therapeutic agent in both cardiology and investigational oncology settings.